Bloomberg News

Regeneron Wins FDA Approval for Blindness Drug Eylea

November 29, 2011

(Adds Eylea price and availability in fifth paragraph.)

Nov. 18 (Bloomberg) -- Regeneron Pharmaceuticals Inc. won U.S. approval of Eylea, a treatment for a common cause of blindness that will rival Roche Holding AG’s Lucentis.

The Food and Drug Administration cleared the injection to treat wet age-related macular degeneration, a leading cause of vision loss in people 60 and older, the company said in a statement today. The drug will hit peak sales of $1.1 billion in 2021 as its use is expanded to other eye disorders, said Yaron Werber, an analyst for Citigroup Inc. in New York.

Eylea can be injected every eight weeks, half as often as Basel, Switzerland-based Roche’s Lucentis. Less frequent dosing may help Eylea capture 16 percent of the U.S. market from Lucentis, Werber said in a telephone interview before the approval was announced.

“We think doctors want to experiment with the drug and there’s a lot of interest,” he said.

Eylea will cost about $1,850 per dose or $16,000 for a year’s treatment, said Robert Terifay, senior vice president for commercial, during a conference call. The drug will be available for doctors to order Nov. 21 and delivered by the next day, he said.

Lucentis, which has about 40 percent of the market, is $2,000 for each monthly injection. Doctors also use Roche’s Avastin, approved to treat certain cancers, on about 60 percent of wet age-related macular degeneration patients. It costs about $50 per injection and is the subject of federal safety reviews after being linked to eye infections.

Lucentis generated $1.4 billion in sales last year.

Earlier Delay

The FDA initially delayed its decision on Aug. 16 saying that answers Regeneron provided to the agency on its application about manufacturing controls were “a major amendment.”

Age-related macular degeneration is a breakdown of the eye’s macula, the part of the eye that allows people to see fine detail needed to do tasks such as reading and driving. In the wet form of the disease, there is abnormal growth of blood vessels that can leak fluid into the macula, leading to vision loss.

Regeneron estimates about 1.5 million people have the wet form of the disease with 200,000 new cases diagnosed each year. Regeneron, based in Tarrytown, New York, fell 2.6 percent to $49.81 at 4 p.m. New York time, before the approval was announced.

--With assistance from Pat Wechsler in New York. Editors: Angela Zimm, Bruce Rule

To contact the reporter on this story: Anna Edney in Washington at

To contact the editor responsible for this story: Adriel Bettelheim at

The Good Business Issue
blog comments powered by Disqus